Table 2. Risk factors for NODAT in adult liver transplant patients (n=1,919).
| Variables | Univariate | Multivariate | |||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P value | ||
| Recipient gender (male) | 1.17 | 0.931–1.469 | 0.178 | ||||
| Recipient age | 1.024 | 1.012–1.036 | <0.001 | 1.022 | 1.010–1.034 | <0.001 | |
| Hypertension in recipients | 1.346 | 1.035–1.750 | 0.027 | ||||
| Body mass index in recipients | 0.003 | 0.003 | |||||
| <18.5 | 1 | 1 | 1 | 1 | |||
| 18.5–24 | 0.728 | 0.460–1.153 | 0.729 | 0.458–1.159 | |||
| 25–29 | 1.029 | 0.642–1.648 | 1.028 | 0.638–1.656 | |||
| ≥30 | 1.245 | 0.712–2.177 | 1.242 | 0.706–2.185 | |||
| Primary liver disease | 0.452 | ||||||
| Alcohol | 1 | 1 | |||||
| Cryptogenic | 1.259 | 0.782–2.025 | |||||
| Hepatitis B virus | 0.946 | 0.739–1.212 | |||||
| Hepatitis C virus | 1.057 | 0.699–1.599 | |||||
| Others | 0.733 | 0.463–1.159 | |||||
| Hepatocellular carcinoma | 0.878 | 0.717–1.075 | 0.208 | ||||
| Disease progression | 0.092 | ||||||
| Cirrhosis | 1 | 1 | |||||
| Acute | 0.938 | 0.584–1.507 | |||||
| Acute on chronic | 0.459 | 0.228–0.926 | |||||
| Child-Pugh class | 0.016 | ||||||
| A | 1 | 1 | |||||
| B | 1.357 | 1.053–1.750 | |||||
| C | 1 | 0.773–1.294 | |||||
| MELD score | 0.175 | ||||||
| <15 | 1 | 1 | |||||
| 15–34 | 1.07 | 0.866–1.322 | |||||
| ≥35 | 0.738 | 0.502–1.085 | |||||
| Urgent status in KONOS | 0.363 | ||||||
| 1 | 1 | 1 | |||||
| 1 (retransplantation) | 2.351 | 0.295–18.739 | |||||
| 2 | 0.64 | 0.276–1.483 | |||||
| 3 | 1.139 | 0.516–2.516 | |||||
| 4 | 0.972 | 0.464–2.035 | |||||
| 5 | 1.075 | 0.532–2.171 | |||||
| Donor type (LDLT) | 1.309 | 1.016–1.686 | 0.037 | ||||
| ABO-incompatible | 1.214 | 0.934–1.577 | 0.15 | ||||
| Liver graft | 0.005 | 0.013 | |||||
| Whole liver | 1 | 1 | 1 | 1 | |||
| Left-side liver graft | 2.22 | 1.364–3.614 | 2.065 | 1.262–3.380 | |||
| Right-side liver graft | 1.283 | 0.989–1.664 | 1.275 | 0.981–1.657 | |||
| Macrosteatosis in liver graft | 0.497 | ||||||
| <10% | 1 | 1 | |||||
| 10–30% | 0.929 | 0.682–1.266 | |||||
| ≥30% | 0.607 | 0.251–1.469 | |||||
| Basiliximab induction | 0.738 | 0.589–0.923 | 0.008 | 0.682 | 0.543–0.855 | <0.001 | |
| Calcineurin inhibitors at discharge | 1.975 | 0.702–9.402 | 0.228 | ||||
| Tacrolimus at discharge | 0.876 | 0.467–1.643 | 0.68 | ||||
| Cyclosporine at discharge | 1.994 | 1.064–3.737 | 0.031 | ||||
| Antimetabolite at discharge | 0.721 | 0.580–0.896 | 0.003 | 0.692 | 0.554–0.863 | 0.001 | |
| Use of mTOR inhibitors at 6 months post-transplant | 0.771 | 0.544–1.091 | 0.142 | ||||
| Steroid at discharge | 2.979 | 1.777–4.993 | <0.001 | 3.144 | 1.842–5.367 | <0.001 | |
| Donor gender (male) | 1.256 | 1.010–1.561 | 0.04 | ||||
| Donor age | 0.992 | 0.985–1.000 | 0.04 | ||||
| Hypertension in donor | 0.866 | 0.568–1.321 | 0.505 | ||||
| Diabetes in donor | 0.818 | 0.437–1.533 | 0.531 | ||||
| Body mass index in donor | 0.38 | ||||||
| <18.5 | 1 | 1 | |||||
| 18.5–24 | 1.239 | 0.737–2.083 | |||||
| 25–29 | 1.047 | 0.603–1.820 | |||||
| ≥30 | 0.845 | 0.358–1.992 | |||||